Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up

The Lancet Oncology

Volumn 9, Issue 12, 2008, Pages 1149-1156

  Mosterd, Klara ^a   Krekels, Gertruud AM ^b   Nieman, Fred HM ^a   Ostertag, Judith U ^b   Essers, Brigitte AB ^a   Dirksen, Carmen D ^a   Steijlen, Peter M ^a   Vermeulen, Anton ^a   Neumann, HAM ^c   Kelleners Smeets, Nicole WJ ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CATHARINA HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FACE CANCER; FEMALE; FOLLOW UP; GRAFT NECROSIS; HEALTH CARE COST; HISTOPATHOLOGY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MOH MICROGRAPHIC SURGERY; NETHERLANDS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; REGRESSION ANALYSIS; RISK FACTOR; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; COST-BENEFIT ANALYSIS; FACIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MOHS SURGERY; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 56449129112     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70260-2     Document Type: Article

References (24)

1. de Vries E., Louwman M., Bastiaens M., de Gruijl F., and Coebergh J.W. Rapid and continuous increases in incidence rates of basal cell carcinoma in the southeast Netherlands since 1973. J Invest Dermatol 123 (2004) 634-638
2. de Vries E., van de Poll-Franse L.V., Louwman W.J., de Gruijl F.R., and Coebergh J.W. Predictions of skin cancer incidence in the Netherlands up to 2015. Br J Dermatol 152 (2005) 481-488
3. Holme S.A., Malinovszky K., and Roberts D.L. Changing trends in non-melanoma skin cancer in South Wales, 1988-98. Br J Dermatol 143 (2000) 1224-1229
4. Bath-Hextall F.J., Perkins W., Bong J., and Williams H.C. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 1 (2007) CD003412.
5. Thissen M.R., Neumann M.H., and Schouten L.J. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol 135 (1999) 1177-1183
6. Rowe D.E., Carroll R.J., and Day Jr. C.L. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 15 (1989) 315-328
7. Rowe D.E., Carroll R.J., and Day Jr. C.L. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 15 (1989) 424-431
8. Kuijpers D.I., Thissen M.R., and Neumann M.H. Basal cell carcinoma: treatment options and prognosis, a scientific approach to a common malignancy. Am J Clin Dermatol 3 (2002) 247-259
9. Silverman M.K., Kopf A.W., Bart R.S., Grin C.M., and Levenstein M.S. Recurrence rates of treated basal cell carcinomas. Part 3: surgical excision. J Dermatol Surg Oncol 18 (1992) 471-476
10. Smeets N.W., Krekels G.A., Ostertag J.U., et al. Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 364 (2004) 1766-1772
11. Zhang M., and Fine J. Summarizing differences in cumulative incidence functions. Stat Med 27 (2008) 4939-4949
12. Essers B.A., Dirksen C.D., Nieman F.H., et al. Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol 142 (2006) 187-194
13. Oostenbrink J., Bouwmans C., Koopmanschap M.A., and Rutten F.F.H. The Dutch manual for costing in economic evaluations (2000), Dutch Health Insurance Board, Amstelveen
14. Efron B., and Tibshirani R. An introduction to the bootstrap (1993), Chapman and Hall, London
15. Leibovitch I., Huilgol S.C., Selva D., Richards S., and Paver R. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol 53 (2005) 452-457
16. Smeets N.W., Kuijpers D.I., Nelemans P., et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face-results of a retrospective study and review of the literature. Br J Dermatol 151 (2004) 141-147
17. Ford I., Norrie J., and Ahmadi S. Model inconsistency, illustrated by the Cox proportional hazards model. Stat Med 14 (1995) 735-746
18. Ford I., and Norrie J. The role of covariates in estimating treatment effects and risk in long-term clinical trials. Stat Med 21 (2002) 2899-2908
19. Telfer N.R., Colver G.B., and Bowers P.W. Guidelines for the management of basal cell carcinoma. British Association of Dermatologists. Br J Dermatol 141 (1999) 415-423
20. Silverman M.K., Kopf A.W., Grin C.M., Bart R.S., and Levenstein M.J. Recurrence rates of treated basal cell carcinomas. Part 1: overview. J Dermatol Surg Oncol 17 (1991) 713-718
21. Rhodes L.E., de Rie M., Leifsdottir R., et al. Five-year follow-up of a randomized prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 143 (2007) 1131-1136
22. Avril M.F., Auperin A., Margulis A., et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76 (1997) 100-106
23. Werlinger K.D., Upton G., and Moore A.Y. Recurrence rates of primary nonmelanoma skin cancers treated by surgical excision compared to electrodesiccation-curettage in a private dermatological practice. Dermatol Surg 28 (2002) 1138-1142
24. Batra R.S., and Kelley L.C. Predictors of extensive subclinical spread in nonmelanoma skin cancer treated with Mohs micrographic surgery. Arch Dermatol 138 (2002) 1043-1051